SSPs aren’t thrilled by TTD characterizing them as “resellers”; Amazon DSP just announced a new partnership to sell Netflix inventory; and pharma brands will be subject to stricter regulations, per the FDA.
The odds of RFK Jr. implementing a ban on TV drug ads are slim, says our guest this week, BranchLab’s Josh Walsh. Still, pharma advertisers could face other regulatory changes over the next four years. Plus: We break down Forrester’s picks for the top 10 SSPs.
Driverless vehicles could become the next hot media channel; FDA reveals new ad guidelines for drug manufacturers; and artists come up with new ways to sabotage generative AI.
History proved that black-box algorithms aimed to optimize business metrics will have severe, harmful consequences that are often not predicted.
Here’s today’s AdExchanger.com news round-up… Want it by email? Sign up here. Tough Math MediaMath came to the end of its decade-long venture capital tether last year when it sold a stake to PE firm Searchlight Capital, wiping out the equity of its founders, early investors and employees. It’s a bitter outcome, reports Insider in […]
Here’s today’s AdExchanger.com news round-up… Want it by email? Sign up here. Trade Desk Trade-Offs The investment bank Needham has both the bullish and bearish takes on The Trade Desk after the DSP reported earnings this month. And there is a compelling case in both directions.
